



Pfizer Advances Trispecific Antibody in Atopic Dermatitis

Pfizer reported positive Phase 2 results for tilrekimig, a trispecific antibody targeting IL-4, IL-13, and TSLP, demonstrating significant improvements in disease severity and a favorable safety profile in moderate-to-severe atopic dermatitis. The program is advancing toward Phase 3 development.

[Read More](#)

Lebrikizumab Shows Long-Term Control and Pediatric Efficacy

Eli Lilly's EBGLYSS® (lebrikizumab) demonstrated sustained disease control and itch relief for up to four years in adults, alongside positive Phase 3 results in pediatric patients, supporting its potential across a broad age range in atopic dermatitis.

[Durability Results](#)

[Pediatric Findings](#)



ICOTYDE Gains FDA Approval and Shows Durable Psoriasis Outcomes

Johnson & Johnson's ICOTYDE™ (icotrokinra), an oral IL-23 receptor inhibitor, received FDA approval for moderate-to-severe plaque psoriasis and demonstrated sustained skin clearance and a favorable safety profile through one year in Phase 3 studies.

[Read More](#)

Aclaris Completes Enrollment in Phase 2 Atopic Dermatitis Trial

Aclaris Therapeutics has completed enrollment in its Phase 2 trial of bosakitug (ATI-045), an anti-TSLP monoclonal antibody, in moderate-to-severe atopic dermatitis, with topline results expected in late 2026.

[Read the Press Release](#)

AAD 2026 Highlights Advances in Dermatology Research

The 2026 American Academy of Dermatology Annual Meeting brought together global experts to share advances across dermatologic conditions, with a focus on emerging therapies, clinical data, and evolving treatment approaches.

[Learn More](#)

Zasocitinib Shows Strong Phase 3 Results in Psoriasis

Takeda's zasocitinib, an oral TYK2 inhibitor, demonstrated rapid and durable skin clearance with a consistent safety profile in Phase 3 plaque psoriasis studies, supporting its potential as a once-daily treatment option.

[Learn More](#)

CPE Spotlight



The following highlights select engagements and programs supported by CPE over the past month.

Conference Attendance

Connected with clients and peers while gaining insights into the latest trends and developments in dermatology

- American Academy of Dermatology Annual Meeting – Denver, Colorado

Below is a list of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

Medical Affairs

- Asynchronous Engagements
- KOL Identification & Contracting
- MOA Visualization
- MSL Training
- Patient Education
- Poster Presentations
- Scientific Platform Development

Medical Affairs + Marketing

- Advisory Boards (Virtual or In-Person)
- Conference Planning
- Content Development
- Core Slide Decks
- KOL Engagements
- Publications

Marketing

- Branding & Visual Aids
- Healthcare Event Production Management
- Launch Preparation
- Product Theater Planning & Logistics
- Speaker Bureau Services
- Speaker Training
- Technical Productions

Across the product lifecycle, CPE drives results through KOL engagement, advisory boards, content, and marketing.

I'd welcome the opportunity to review a customized overview of our capabilities for your team and explore potential collaboration.

With appreciation,

Allison Goldberg, MPA
Associate Vice President
CPE Communications
Cell: 917-509-9583
agoldberg@cpeducate.com



When you're ready to explore how the CPE Communications Team can support your company, contact Allison at agoldberg@cpeducate.com

